References
- CBS Statline open data. Family planning; contraceptive method and woman’s age; 1993–2013. Available from: https://opendata.cbs.nl/#/CBS/nl/dataset/37459/table?ts = 1516890667324.
- Geirsson RT, Gemzell-Danielsson K. Heavy menstrual bleeding and quality of life. Acta Obstet Gynecol Scand. 2014;92:617–618.
- Gemzell-Danielsson K, Inki P, Heikinheimo O. Recent developments in the clinical use of thelevonorgestrel-releasing intrauterine system. Acta Obstet Gynecol Scand. 2011;90:1177–1188.
- Long ME, Faubion SS, MacLaughlin KL, et al. Contraception and hormonal management in the perimenopause. J Womens Health. 2015;24:3–10.
- Grimes DA, Lopez LM, Manion C, et al. Cochrane systematic reviews of IUD trials: lessons learned. Contraception. 2007;75:S55–S9.
- Patseadou M, Michala L. Usage of the levonorgestrel-releasing intrauterine system (LNG- IUS) in adolescence: what is the evidence so far? Arch Gynecol Obstet. 2017;295:529–541.
- Dickerson LM, Diaz VA, Jordon J, et al. Satisfaction, early removal and side effects associated with long-acting reversible contraception. Fam Med. 2013;45:701–707.
- Hall AM, Kutler BA. Intrauterine contraception in nulliparous women: a prospective survey. J Fam Plann Reprod Health Care. 2016;42(1):36–42.
- Soriano LC, Wallander M, Andersson S, et al. The continuation rates of long-acting reversible contraceptives in UK general practice using data from The Health Improvement Network. Pharmacoepidemiol Drug Saf. 2015;24:52–58.
- Aoun J, Dines VA, Stovall DW, et al. Effects of age, parity, and device type on complications and discontinuation of intrauterine devices. Obstet Gynecol. 2014;123:585–592.
- Kriplani A, Singh BM, Lal S, et al. Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia. Int J Gynaecol Obstet. 2007;97:190–194.
- Short M, Dallay D, Omokanye S, et al. Acceptability of long-acting, progestin-only contraception in Europe: a two year prospective, non-interventional study. Eur J Contracept Reprod Health Care. 2014;19:29–38.
- Kaislasuo J, Heikinheimo O, Lähteenmäki P, et al. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception. Hum Reprod. 2015;30(7):1580–1588.
- O’Neil ME, Jeffrey FP, Qiuhong Z, et al. Twenty-four-month continuation of reversible contraception. Obstet Gynecol. 2013;122:1083–1091.
- Rosenstock JR, Jeffrey FP, Madden T, et al. Continuation of reversible contraception in teenagers and young women. Obstet Gynecol. 2012;120:1298–1305.
- Philips SJ, Hofler LG, Modest AM, et al. Continuation of copper and levonorgestrel intrauterine devices: a retrospective cohort study. Am J Obstet Gynaecol. 2017;217:57e1–57e6.
- Weisberg E, Bateson D, McGeechan K, et al. Three-year comparative study of continuation rates, bleeding patterns and satisfaction in Australian women using a subdermal contraceptive implant or progestogen releasing-intrauterine system. Eur J Contracept Reprod Health Care. 2014;19:5–14.
- Megha S, Shubham J, Oby N, et al. Determinants of intrauterine contraceptive device: discontinuation among Indian women. J Obstet Gynaecol India. 2014;64:208–211.
- Backman T, Huhtala S, Blom T, et al. Length of use and symptoms associated with prematureremoval of the levonorgestrel intrauterine system: a nation-wide study of 17,360 users. BJOG. 2000;107:335–339.
- Rose S, Chaudhari A, Peterson CM. Mirena (Levonorgestrel intrauterine system): a successful novel drug delivery option in contraception. Adv Drug Deliv Rev. 2009;61:808–812.
- Modesto W, Bahamondes MV, Bahamondes L. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives. Hum Reprod. 2014;29:1393–1399.
- Wellings K, Brima N, Sadler K, et al. Stopping and switching contraceptive methods: findings from contessa, a prospective longitudinal study of women of reproductive age in England. Contraception. 2014;9:57–66.
- Grunloh DS, Casner T, Secura GM, et al. Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use. Obstet Gynecol. 2013;122:1214–1221.
- Wildemeersch D, Goldstuck ND, Jackers G. Results of a 5-year contraceptive trial in parous and nulliparous women with a new LNG-IUS. Gynecol Endocrinol. 2017;33:223–226.
- Heineman K, Reed S, Moehner S, et al. Risk of uterine perforation withlevonorgestrel- releasing and copper intrauterine devices in the European active surveillance study on intrauterine devices. Contraception. 2015;91:274–279.